Publish with Us

GenoMed Connect

Hanieh Yaghootkar
Editor-in-Chief

Hanieh Yaghootkar
Editor-in-Chief

View Profile

GenoMed Connect facilitates interdisciplinary collaboration in advancing genomic integration into medicine. We welcome diverse contributions covering genomic medicine, translational genomics, precision medicine, human genetics, microbial genomics, technological advances, and ethical/social implications.  This open-access journal follows a continuous publication model and is licensed under Creative Commons Attribution 4.0 (CC BY 4.0).

Volumes 3
Articles 18
Volume: 3, 2026

Insights

46 Days

Time to First Peer Review Decision

78 Days

Time to Final Acceptance

3 Days

Acceptance to First Online


Recent Articles

Review Article

Available Online: 30 Dec 2025

Spatial Omics in Decoding Oral Squamous Cell Carcinoma Heterogeneity: Microenvironment Crosstalk and Multi-Omics Integration

Volume 2

Oral squamous cell carcinoma (OSCC) is a major issue in the sphere of head and neck cancer since it is very heterogeneous, which also leads to the poor treatment results and low survival rates in the advanced stages. Here, the review will discuss how spatial omics methods explore tumor heterogeneity in OSCC, which includes cellular, molecular, and immune microenvironment alterations..

Editorial

Published: 03 Oct 2025

Current Insights into Pharmacogenomics of Noncoding RNAs for Cancer Therapy

Volume 2

Cancer remains a significant global health challenge, with varying incidence and mortality rates across the globe. According to the Surveillance, Epidemiology, and End Results (SEER) registry [1] and the American Cancer Society (ACS) [2], more than 2 million new cancer cases are expected in the US by 2025. Understanding the burden of disease and advancements in tailored treatments, also known..

Review Article

Published: 24 Jun 2025

Epigenetic Insights into Bladder Cancer: The Role of Urine DNA Methylation Assays: Mini Review

Volume 2

Bladder cancer remains a major global health challenge due to its high incidence, recurrence rates, and reliance on invasive diagnostic procedures. While conventional methods, such as cystoscopy and urine cytology, are considered standard, they often demonstrate limited sensitivity, particularly in detecting early-stage disease. Epigenetic alterations, particularly DNA methylation, are now recognized as critical in bladder cancer development and progression. Non-invasive..